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Introduction
Gadobenate dimeglumine (Gd-BOPTA) is a relatively new
paramagnetic contrast agent that produces two-fold
higher T1 relaxivity compared with gadopentetate dimeg-
lumine (Gd-DTPA). Importantly however, it is not known
whether Gd-BOPTA is efficacious for identifying chroni-
cally infarcted tissue in subjects with ischemic cardiovas-
cular disease.
Purpose
To determine the association between myocardial infarct
size identified with delayed enhancement imaging using
lower dose (0.1 mmol/kg) of Gd-BOPTA versus standard
dose 0.2 mmol/kg of Gd-DTPA.
Methods
Twenty participants (16 men, 4 women) aged 58 ± 12
years who sustained chronic myocardial infarction (MI)
were enrolled and provided written informed consent.
Using a double-blind, cross-over design, each participant
underwent delayed enhancement images of the left ventri-
cle 10 minutes after the intravenous administration of
contrast on 2 separate occasions separated by 3 to 7 days.
During one exam, participants received 0.2 mmol/kg of
Gd-DTPA, and on the other, they received 0.1 mmol/kg of
Gd-BOPTA. Voxels displaying delayed enhancement (DE)
were identified as having an intensity of > 2 standard devi-
ations above those voxels in non-infarct myocardium.
Paired Student's t-tests and McNemar's tests were per-
formed to determine the differences of infarct size, signal
intensities (SIs), and transmural extent of infarct tissue.
Cohan's kappa statistic was used to measure degree of
agreement between two contrast agents for the location of
infarcts.
Results
A total of 320 myocardial segments were analyzed. The
mean ± standard deviation of Infarct size was 31.7 ± 21
(range 0 to 88.7) ml. The correlations and inter-contrast
reliabilities of infarct size in ml were high (0.91 and 0.91),
respectively. The contrast-to-noise ratio (CNR) of the inf-
arcted and normal myocardium (p = 0.25), and signal-to-
noise ratio (SNR) of infarcted myocardium (p = 0.23)
were similar in both contrast agents. There was no signifi-
cant difference between the 2 contrast agents in the
number (p = 0.4) and location (k = 0.6–1) of myocardial
segments displaying DE, as well as the number of seg-
ments identifying > 50% or < 50% transmurality DE (p =
0.9).
Conclusion
In the setting of chronic myocardial infarction, delayed
enhancement identified with a single 0.1 mmol/kg dose
of Gd-BOPTA is associated in size, SIs, location, and sever-
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